ClinicalTrials.gg
Active, not recruitingNCT05692180DOMINICAUpdated Nov 16, 2026

A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma

A Phase 3 interventional study of Benralizumab and Placebo in Asthma, sponsored by AstraZeneca. Active, not recruiting at 43 sites in 9 countries. Open to participants aged 6 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
94
Allocation
Randomized
Ages
6 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies testing benralizumab in Asthma — 3 open to participants now, 4 under way, 2 of them phase 3. benralizumab · Asthma.

Enrollment
26th of 39
94 · median 128
Started
2023
the only one that year
Phase 3
20 of 39
1 open now
Registered
35th of 39
by date
Lead sponsor
24 of 39
AstraZeneca

Among the 39 studies testing benralizumab in Asthma, this one is the 26th largest by enrollment, is the only one that started in 2023, is one of 20 in phase 3, and was the 35th registered.

Asthma

4,849 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

3 of the 39 studies testing benralizumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About benralizumab

benralizumab: first FDA approval 2017 (FASENRA), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 416 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: 6 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies testing benralizumab in Asthma, or all of them as a file.
02

Study summary

A study to evaluate the efficacy and safety of benralizumab administered subcutaneously in patients ≥ 6 to \< 18 years of age with severe eosinophilic asthma, including a well-documented history of asthma exacerbations and uncontrolled asthma receiving high-dose inhaled corticosteroid (ICS) plus at least one additional controller medication.

Read the detailed description

A randomised, double-blind, parallel-group, placebo-controlled, time-to-first-asthma-exacerbation event study designed.

There will be a screening period of 2 months to allow adequate time for the eligibility criteria to be evaluated. The screening period may be reduced to not lesser than 4 weeks from Visit 2a. Furthermore, the Screening Period may be extended up to 12 weeks (or longer, if deemed necessary by the investigator), to accommodate treatment.

Visit 2 will be split into Part A (Visit 2a) and Part B (Visit 2b) to reassess eligibility prior to randomisation and first dose of study treatment administration.

Patients will be randomised 1:1 to receive benralizumab or placebo.

The treatment period will consist of 2 parts: double-blind (DB) treatment period and open-label extension (OLE) period.

The initial placebo-controlled, DB treatment period will be of variable duration. The minimum duration of treatment in the DB treatment period for each patient will be 16 weeks. Patient will continue in the DB treatment period until the patient experiences an exacerbation or the required number of events have been observed in the study, whichever occurs sooner.

All patients who experience an asthma exacerbation in the DB treatment period will be offered the opportunity to continue into the OLE period. The OLE period is intended to allow each patient at least 48 weeks in the ≥ 12 to \< 18-year-old age group and at least 2 years (104 weeks) in the ≥ 6 to \< 12-year-old age group, of treatment with benralizumab.

An end-of-the-treatment visit will occur 8 weeks after the last dose in the OLE.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Eosinophilic asthma
  • Pediatric Patients
  • Severe asthma
04

Who can participate

Ages eligible
6 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Capable of giving assent (signing the assent form) to participate in the study. The caregiver of the patient must be capable of giving written for the patient's participation in the study. Consent and assent forms must be completed prior to any study-specific procedures.
  • Patient and the caregiver (where applicable) must be willing to and be able to answer questionnaires that are part of the study procedures.
  • Male or female patients aged ≥ 6 to \< 18 years old.
  • Patients with physician-diagnosed severe eosinophilic asthma for at least 12 months prior to Visit 1.
  • Patients with a diagnosis of severe asthma confirmed, evaluated, and managed by the clinical site/site network for ≥ 6 months prior to Visit 1.
  • Patients with an exacerbation history of asthma exacerbations (defined as a requirement for systemic and/or hospitalisation) within 12 months prior to Visit 1, OR,

    1. 2 asthma exacerbations (defined as a requirement for systemic corticosteroids and/or hospitalisation) per year within the 2 years prior to Visit 1 AND, one or more of the following:
    2. Currently on stable maintenance oral corticosteroids (OCS) used for at least 3 months prior to Visit 1, OR,
    3. At least one of the 2 exacerbations that occurred in the year prior to Visit 1 resulted in hospitalisation.
  • Patients on well-documented, stable treatment for asthma with high dose ICS and at least one additional controller medication, such as long-acting β2 agonists (LABA), leukotriene receptor antagonists (LTRA), long-acting muscarinic antagonists (LAMA), or theophylline, since at least 6 months prior to Visit 1.
  • Eosinophilic airway inflammation that is related to asthma characterised as eosinophilic in nature as indicated by peripheral blood eosinophil count of ≥ 300 cells/μL during screening OR a blood eosinophil count of 150 to 299 cells/μL and documentation of elevated eosinophils in bronchoalveolar lavage (BAL), sputum or bronchial within the 2 years prior to Visit 1.
  • ≥ 70% compliance with maintenance asthma medication during the screening period based on the Paediatric Asthma Symptom - Observer reported (PASO) or Asthma Daily Diary.
  • At least 70% daily PASO or Asthma Daily Diary completion during the entire screening period, with at least 50% PASO or Asthma Daily Diary completion in the 14-day period prior to randomisation.
  • Pre-BD ≤ 95% of the predicted normal value or pre-BD FEV1/forced vital capacity (FVC) ratio \< 0.85 required at Visit 1. Patients with ≥ 25 % increase in pre-BD FEV1 value during the screening period will be screen failed.
  • ACQ-IA ≥ 1.5 with no meaningful improvement (ACQ-IA change ≤ -0.5) between screening and Visit 2a.
  • Body weight ≥ 15 kg.
  • Females of (FOCBP) who are sexually active, as judged by the investigator, must commit to consistent and correct use of a highly effective method of .

Exclusion criteria

Exclusion Criteria:

  • pulmonary disease other than asthma or patients who have ever been diagnosed with pulmonary or systemic disease, other than asthma, that are associated with elevated peripheral eosinophil counts.
  • Life-threatening asthma.
  • Asthma exacerbation requiring use of systemic or increase in maintenance dose of OCS within 2 weeks prior to Visit 2a or acute upper/lower respiratory infection that requires antibiotics or antiviral medication within 2 weeks prior to the first dose of the IP (Visit 2b).
  • Any disorder that is not stable in the opinion of the investigator and could affect the safety of the patient during the study, influence the findings of the studies or their interpretations or impede the patient's ability to complete the entire duration of the study.
  • History of anaphylaxis to any biologic therapy.
  • Current , or history of malignancy.
  • A helminth parasitic infection.
  • Use of medication.
  • Receipt of immunoglobulin or blood products within 30 days prior to Visit 1.
  • Receipt of any marketed or biologic within 5 half-lives prior to Visit 1.
  • Previously received benralizumab (MEDI-563).
  • Participation in another interventional clinical study.
  • Patients with known to benralizumab or any of the of the product.
  • Currently pregnant, breastfeeding, or lactating females.
  • Previous randomisation in the present study.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
94 participants (actual)

Study arms

  • Experimental
    Benralizumab

    Patients will receive Benralizumab as an active solution via a subcutaneous (SC) injection.

    Drug: Benralizumab

  • Placebo comparator
    Placebo

    Patients will receive a matching solution of the placebo via SC injection.

    Drug: Placebo

Interventions

  • Benralizumab active solution will be administered SC to the patients.

  • DrugPlacebo

    Placebo solution will be administered SC to the patients.

06

What researchers measure

Primary outcomes

  1. Time to first asthma exacerbation

    The effect of benralizumab on asthma exacerbations in paediatric and adolescent patients with uncontrolled asthma will be evaluated.

    Time frame: From Baseline (Week 0) to End of Treatment (EOT) in DB treatment period

Secondary outcomes

  1. Change from baseline, during the DB treatment period in Interviewer-Administered Version of the Asthma Control Questionnaire (ACQ-IA)

    The effect of benralizumab on asthma control and symptoms will be assessed.

    Time frame: From Baseline (Week 0) to EOT in DB treatment period

  2. Change from baseline, during the DB treatment period in Asthma symptom score

    The effect of benralizumab on asthma control and symptoms will be assessed.

    Time frame: From Baseline (Week 0) to EOT in DB treatment period

  3. Change from baseline, during the DB treatment period in rescue medication use

    The effect of benralizumab on asthma control and symptoms will be assessed.

    Time frame: From Baseline (Week 0) to EOT in DB treatment period

  4. Change from baseline, during the DB treatment period in night-time awakenings due to asthma

    The effect of benralizumab on asthma control and symptoms will be assessed.

    Time frame: From Baseline (Week 0) to EOT in DB treatment period

  5. Change from baseline, during the DB treatment period in peak expiratory flow (PEF)

    The effect of benralizumab on asthma control and symptoms will be assessed.

    Time frame: From Baseline (Week 0) to EOT in DB treatment period

  6. Serum benralizumab trough concentration

    The pharmacokinetics of benralizumab will be characterised.

    Time frame: During Day -7, Day 56, Day 112, every 16 weeks and at EOT DB treatment period

  7. Anti-benralizumab antibodies

    The immunogenicity of benralizumab will be characterised.

    Time frame: During Day -7, Day 56, Day 112, every 16 weeks and at EOT DB treatment period

  8. Change from baseline, during the DB treatment period in Paediatric Asthma Quality of Life Questionnaire-Interviewer Administered (PAQLQ-IA) total score

    The effect of benralizumab on asthma health-related quality of life will be assessed.

    Time frame: From Baseline (Week 0) to EOT in DB treatment period

  9. Change from baseline, during the DB treatment period, in spirometry, for pre-dose/pre-bronchodilator forced expiratory volume in one second (FEV1)

    The effect of benralizumab on pulmonary function (FEV1) will be assessed.

    Time frame: From Baseline (Week 0) to EOT in DB treatment period

  10. Change from baseline, during the DB treatment period, in spirometry, for post-bronchodilator FEV1

    The effect of benralizumab on pulmonary function (FEV1) will be assessed.

    Time frame: From Baseline (Week 0) to EOT in DB treatment period

  11. The Annualised asthma exacerbation rate (AAER) in the DB treatment period

    The asthma exacerbations reported during the DB treatment period of the study will be described.

    Time frame: From Screening until the EOT double blind treatment period

Other outcomes

  1. Number of patients with Adverse events (AEs) and Serious adverse events (SAEs)

    The safety and tolerability of benralizumab will be evaluated.

    Time frame: From Screening period until EOT DB treatment period

  2. The AAER in the OLE period

    The annualised rate of severe exacerbations in the OLE period will be assessed.

    Time frame: From Week 0 until the EOT OLE period

07

Study locations

43 sites
  • Research Site
    Torrance, California 90505, United States
  • Research Site
    Ocala, Florida 34471, United States
  • Research Site
    Owensboro, Kentucky 42301, United States
  • Research Site
    Lafayette, Louisiana 70508, United States
  • Research Site
    Kansas City, Missouri 64108, United States
  • Research Site
    Northfield, New Jersey 08225, United States
  • Research Site
    The Bronx, New York 10459, United States
  • Research Site
    Cincinnati, Ohio 45229, United States
  • Research Site
    Charleston, South Carolina 29425, United States
  • Research Site
    San Antonio, Texas 78229, United States
  • Research Site
    Tyler, Texas 75708, United States
  • Research Site
    Ciudad de Buenos Aires, C1414AIF, Argentina
  • Research Site
    Ciudad de Buenos Aire, C1425DTG, Argentina
  • Research Site
    Florida, B1602DQD, Argentina
  • Research Site
    Lobos, 7240, Argentina
  • Research Site
    Mar del Plata, B7600, Argentina
  • Research Site
    Mendoza, 5500, Argentina
  • Research Site
    Mendoza, M5500CCG, Argentina
  • Research Site
    Rosario, 2000, Argentina
  • Research Site
    San Juan Bautista, 1888, Argentina
  • Research Site
    Santa Fe, S3000ASF, Argentina
  • Research Site
    Créteil, 94010, France
  • Research Site
    Lyon, 69394, France
  • Research Site
    Rouen, 76031, France
  • Research Site
    Milan, 20142, Italy
  • Research Site
    Roma, 00165, Italy
  • Research Site
    Bialystok, 15-879, Poland
  • Research Site
    Krakow, 31-624, Poland
  • Research Site
    Lodz, 90-302, Poland
  • Research Site
    Skarżysko-Kamienna, 26-110, Poland
  • Research Site
    Tarnów, 33-100, Poland
  • Research Site
    Cheongju-si, 28644, South Korea
  • Research Site
    Junggu, 22332, South Korea
  • Research Site
    Seoul, 03080, South Korea
  • Research Site
    Seoul, 05505, South Korea
  • Research Site
    Badalona, 08916, Spain
  • Research Site
    Barcelona, 8035, Spain
  • Research Site
    Benalmádena, 29631, Spain
  • Research Site
    Esplugues de Llobregat, 8950, Spain
  • Research Site
    Kaohsiung City, 833, Taiwan
  • Research Site
    Taoyuan, 333, Taiwan
  • Research Site
    London, SE5 9RS, United Kingdom
  • Research Site
    Manchester, M13 9PL, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for Dec 2026, 44 months after the start.

Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's planned 44 months is above that.

Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 11, 2023
First posted
Jan 20, 2023
StartActual
Apr 5, 2023
Primary completionEst.
Dec 23, 2026
CompletionEst.
Dec 23, 2026
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
2 updates, last Nov 16, 2026
Show all 2 updates
  1. Nov 16, 2026
    Minor edits only
    + 1 other change: verification date
  2. Oct 28, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05692180
Lead sponsor
AstraZeneca
Collaborators
Parexel
Responsible party
Sponsor
First posted
Jan 20, 2023
Start date
Apr 5, 2023
Primary completion
Dec 23, 2026 (estimated)
Completion
Dec 23, 2026 (estimated)
Last update
Nov 16, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Benralizumab

Start the discussion